Relation of Sociodemographic Factors With Primary Cause of Hospitalization Among Patients With Left Ventricular Assist Devices (from the National Inpatient Sample 2012 to 2017)
Introduction
Left ventricular assist devices (LVADs) are an established intervention that provide mechanical circulatory support for patients with end-stage heart failure (HF).1,2 Despite improvement in outcomes after the introduction of continuous-flow LVADs (cfLVADs) in 2008,3 rehospitalization for complications remain common.4 According to recent North American data, 38.6% and 72.2% of patients receiving an LVAD are rehospitalized within 90 days and 1 year of implantation.4 Given this continued burden of rehospitalization, understanding the sociodemographic characteristics of this rehospitalized population is of great importance. Although previous studies have investigated the association of sociodemographic factors with outcomes after LVAD implantation,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 there is a dearth of national-level data on the association of sociodemographic factors with specific causes of hospitalization, especially key severe adverse events, with significant implications for morbidity and mortality.4,18 In this study, we use hospitalization data from the National Inpatient Sample to address this gap in knowledge. We hypothesized that the frequency in which specific adverse events are the primary cause of rehospitalizations after LVAD placement differs by sociodemographic and economic markers.
Section snippets
Methods
In this retrospective cohort study, we used hospitalization data from the Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project National Inpatient Sample from January 1, 2012 to December 31, 2017. This database is an approximately 20% sample of all civilian inpatient discharges from community hospitals in the United States, regardless of payer, which can be weighted to provide national estimates of hospitalizations and is the largest such publicly available source
Results
Demographics for hospitalizations of patients with LVAD, occurring after initial device placement for each year from 2012 to 2017 are presented in Table 1. Among the 62,630 identified hospitalizations, 41% (n = 25,945) were aged ≥65 years, 77% (48,190) were men, 26% (16,015) were Black, 5% (3,145) were Hispanic, and a majority were in the lowest income quartiles (54%, 33,635 in quartile 1 and 2 combined). The vast majority of patients lived in an urban area (84%, 52,485) and were hospitalized
Discussion
In this study, we investigated the association of sociodemographic factors with the primary causes of rehospitalization among patients who had undergone previous LVAD placement. We found significant differences in the frequency of key diagnoses by sociodemographic factors, including age, gender, race/ethnicity, insurance status, and income level.
Despite significant improvements in LVAD technology, complications remain common. Previous studies have reported comparable perioperative outcomes by
Disclosures
The authors have no conflicts of interest to declare.
Acknowledgment
This study used hospitalization data from the National Inpatient Sample which is contributed to from the following state data partners: Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio,
References (29)
- et al.
American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J Am Coll Cardiol
(2013) - et al.
The Society of Thoracic Surgeons intermacs 2020 annual report
Ann Thorac Surg
(2021) - et al.
Gender differences in outcomes after implantation of left ventricular assist devices
Ann Thorac Surg
(2020) - et al.
Contemporary left ventricular assist device outcomes in an aging population: an STS INTERMACS analysis
J Am Coll Cardiol
(2021) - et al.
Hospital complications and causes of 90-day readmissions after implantation of left ventricular assist devices
Am J Cardiol
(2018) - et al.
Comparison of trends, mortality, and readmissions after insertion of left ventricular assist devices in patients <65 years vs ≥65 years
Am J Cardiol
(2020) - et al.
National landscape of unplanned 30-day readmissions in patients With left ventricular assist device implantation
Am J Cardiol
(2018) - et al.
Sex differences in patients receiving left ventricular assist devices for end-stage heart failure
JACC Heart Fail
(2020) - et al.
The Society of Thoracic Surgeons intermacs 2019 annual report: the changing landscape of devices and indications
Ann Thorac Surg
(2020) - et al.
International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary
J Heart Lung Transplant
(2013)
ADVANCE Trial Investigators. The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies
JACC Heart Fail
Implantable cardioverter-defibrillators in patients with a continuous-flow left ventricular assist device: an analysis of the INTERMACS Registry
JACC Heart Fail
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the Heart Failure Society of America
Circulation
Advanced heart failure treated with continuous-flow left ventricular assist device
N Engl J Med
Cited by (2)
Hyoid Bone Syndrome in a Patient Undergoing Left Ventricular Assist Device Implantation
2023, Healthcare (Switzerland)
This research was supported in part by the National Center for Advancing Translational Sciences (NCATS), Bethesda, Maryland, a component of the National Institutes of Health, Bethesda, Maryland, under award No. UL1TR003017.